Nordion (NDZ) posts a mixed FQ2, missing on a per share basis but beating on revenue. Total sales rose by 12% Y/Y, but net profit fell 77% as the medical-technology company posted significantly higher selling and administrative expenses. Targeted-therapies revenue was up 6.1%, while sterilization-technologies sales jumped 36%. Sales in the medical-isotopes segment however, were roughly flat. Total costs and expenses grew 17%, as SG&A costs rose 58%.